BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 15987919)

  • 1. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
    N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
    Beniaminovitz A; Itescu S; Lietz K; Donovan M; Burke EM; Groff BD; Edwards N; Mancini DM
    N Engl J Med; 2000 Mar; 342(9):613-9. PubMed ID: 10699160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation.
    Joyal D; Cantarovich M; Cecere R; Giannetti N
    Clin Transplant; 2004 Oct; 18(5):493-6. PubMed ID: 15344949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
    N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
    Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL; Hardie I; Johnson RW; Lin A; Nashan B; Pescovitz MD; Ramos E; Vincenti F;
    Transplantation; 2001 Sep; 72(5):839-45. PubMed ID: 11571447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
    Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
    Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.